MedTrace Logo

S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer

NCT01671449 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 338

Last updated 2015-11-30

No results posted yet for this study

Summary

A multicenter, randomized, open-label, phase III trial of S-1 plus cisplatin (3 weekly) versus S-1 plus oxaliplatin chemotherapy for the first-line treatment of advanced gastric cancer

Conditions

Interventions

DRUG

S-1

S-1 : 40 mg/m2, twice daily, Day 1-14

DRUG

Cisplatin

60 mg/m2/day Day 1

DRUG

Oxaliplatin

130 mg/m2/day Day 1

Sponsors & Collaborators

  • Min-Hee Ryu

    lead OTHER

Principal Investigators

  • Min-Hee Ryu, M.D., Ph.D · Asan Medical Center

  • Young-Iee Park, MD., Ph.D. · National Cancer Center, Seoul, Korea

  • Ik-Joo Chung, MD., Ph.D. · Chonnam National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-10-31
Completion
2015-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01671449 on ClinicalTrials.gov